Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 4
1986 2
1987 1
1988 5
1989 5
1990 6
1991 1
1992 3
1993 7
1994 5
1995 5
1996 2
1997 2
1998 3
1999 6
2000 4
2001 7
2002 3
2003 5
2004 7
2005 6
2006 5
2007 6
2008 16
2009 21
2010 15
2011 22
2012 31
2013 15
2014 25
2015 26
2016 22
2017 15
2018 12
2019 17
2020 19
2021 21
2022 12
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD; DISCOVER study team. Ogbuagu O, et al. Among authors: podzamczer d. Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0. Lancet HIV. 2021. PMID: 34197772 Clinical Trial.
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.
Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group. Rodger AJ, et al. Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2. Lancet. 2019. PMID: 31056293 Free PMC article.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Orkin C, et al. Among authors: podzamczer d. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. Lancet HIV. 2020. PMID: 32504574 Clinical Trial.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Among authors: podzamczer d. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
[Introduction. Rilpivirine].
Podzamczer D. Podzamczer D. Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:1. doi: 10.1016/S0213-005X(13)70135-6. Enferm Infecc Microbiol Clin. 2013. PMID: 24252526 Spanish. No abstract available.
Switching strategies in the recent era of antiretroviral therapy.
Prieto P, Podzamczer D. Prieto P, et al. Among authors: podzamczer d. Expert Rev Clin Pharmacol. 2019 Mar;12(3):235-247. doi: 10.1080/17512433.2019.1575728. Epub 2019 Feb 13. Expert Rev Clin Pharmacol. 2019. PMID: 30691315 Review.
Past and future of HIV infection. A document based on expert opinion.
Bouza E, Arribas JR, Alejos B, Bernardino JI, Coiras M, Coll P, Del Romero J, Fuster MJ, Górgolas M, Gutiérrez A, Gracia D, Hernando V, Martínez-Picado J, Martínez Sesmero JM, Martínez E, Moreno S, Mothe B, Navarro ML, Podzamczer D, Pulido F, Ramos JT, Ruiz-Mateos E, Suárez García I, Palomo E. Bouza E, et al. Among authors: podzamczer d. Rev Esp Quimioter. 2022 Apr;35(2):131-156. doi: 10.37201/req/083.2021. Epub 2022 Jan 12. Rev Esp Quimioter. 2022. PMID: 35018404 Free PMC article. Review.
Switch strategies in antiretroviral therapy regimens.
Van den Eynde E, Podzamczer D. Van den Eynde E, et al. Among authors: podzamczer d. Expert Rev Anti Infect Ther. 2014 Sep;12(9):1055-74. doi: 10.1586/14787210.2014.944506. Epub 2014 Jul 30. Expert Rev Anti Infect Ther. 2014. PMID: 25075752 Review.
363 results